Completed PHASE4 INTERVENTIONAL 2-arm NCT01057251

Nebivolol in Patients With Systolic Stage 2 Hypertension (NEB-MD-20)

Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of 5 mg or 20 mg Nebivolol Once Daily on Blood Pressure in Patients With Systolic Stage 2 Hypertension

Sponsor: Forest Laboratories

Conditions Hypertension

Interventions Nebivolol Placebo

Updated 7 times since 2017 Last updated: Dec 6, 2011 Started: Mar 31, 2010 Primary completion: Dec 31, 2010 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Hypertension and is currently completed. Forest Laboratories leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories

Data source: Forest Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Auburn, United States , Augusta, United States , Baltimore, United States , Charleston, United States , Chino, United States , Coral Gables, United States , Corpus Christi, United States , Daytona Beach, United States , Florissant, United States and 23 more locations